ISR Expands Biosimilar Library with Two New Reports
Industry Standard Research (ISR) announced the release of two new reports focused on the Biosimilar industry. “US Payers and Biosimilar Formulary Placement” and “Biosimilars: A View from the Pharmacy” expand the base of knowledge regarding Biosimilar market dynamics. These reports look at how these two segments of the healthcare delivery system view, among other things, Biosimilar pricing, formulary placement, pharmacy-level substitution, and clinical trial requirements.
“This is our third installment in our Biosimilar Primer series. We are starting to see physicians, pharmacists, and payers having very different views on how they see the landscape of Biosimilars unfolding.” explained Andrew Schafer, President of Industry Standard Research.
One interesting data point from the “US Payers and Biosimilar Formulary Placement” report is that while very few payer organizations have a separate formulary tier for Biosimilars today, in two years the adoption of a separate tier is expected to climb substantially.
These reports provide pharmaceutical companies, contract research organizations, marketing, and consulting companies with baseline views of how these constituents view some major topics relating to Biosimilars. The data contained in all three of ISR’s Biosimilar Primer series can be used as foundational elements for an organization’s strategic planning around Biosimilars.
“The Biosimilar market is one that is obviously heating up. We have seen several recent announcements around development programs and/ or partnerships designed to develop and commercialize Biosimilars. ISR will continue to monitor this industry and we are planning a Patient Recruitment in Biosimilar Trials report later this year to help round out our subscriber’s knowledge base.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
